<DOC>
	<DOCNO>NCT01755559</DOCNO>
	<brief_summary>Study treatment : - Artemether-lumefantrine - Artesunate-amodiaquine - Dihydroartemisinin-piperaquine Location : Maradi , Niger Principal Objective : To measure clinical parasitological efficacy three artemisinin combination therapy period 42 day start treatment polymerase chain reaction assay ( PCR ) adjustment . Secondary objective : - To determine blood concentration non-artemisinin component treatment ( lumefantrine , desethylamodiaquine piperaquine ) day 7 - To assess incidence adverse event follow-up period ; - To measure speed parasite clearance Methods : In vivo non comparative study WHO standardise protocol . The study also measure concentration non-artemisinin component . Target population : Children 5 year age consulting integrate health centre Andoumé Dix-sept port Maradi . Sample size : 221 patient per study treatment ; 663 patient total . Treatment allocation : Random . Outcomes : - Early treatment failure , - Late clinical failure , - Late parasitological failure , - Adequate clinical parasitological response . Analysis : - Cumulative success failure rate ( Kaplan-Meier analysis ) . - Proportions early treatment failure , late clinical failure , late parasitological failure , adequate clinical parasitological response ( call also Per-protocol analysis ) .</brief_summary>
	<brief_title>Efficacy Three ACTs Treatment Falciparum Malaria Maradi Niger</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>Age 6 59 month Weight ≥ 5 kg Monoinfection P. falciparum detect microscopy Parasitic density 2,000 200,000 asexual form /µL blood Axillary temperature ≥ 37.5°C history fever previous 24 hour Ability willingness comply protocol duration study comply study visit schedule ( home within one hour walk outpatient department , nearterm travel plan , etc . ) Consent parent guardian least 18 year age . Presence general danger sign define WHO , Presence sign severe malaria accord definition WHO , Severe anemia ( haemoglobin &lt; 5 g/dL ) , Known history symptomatic cardiac arrhythmia clinically relevant bradycardia , Family history sudden death congenital prolongation correct QT interval , Use antiarrhythmic neuroleptic , Known history hypersensitivity study medication , Severe malnutrition ( defined weightheight ratio &lt; 3 zscore accord 2006 WHO reference ( 20 ) / midupper arm circumference low 115 mm / presence symmetrical oedema foot ) , Presence febrile condition due disease malaria ( i.e . measles , acute low respiratory tract infection , otitis medium , tonsillitis , abscess , severe diarrhoea dehydration , etc . ) History full treatment course one three study drug past 28 day . The prior incomplete intake one three study drug prior intake antimalarial drug test study exclude patient participate study . However , information previous treatment carefully record .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>malaria</keyword>
	<keyword>artemisinin</keyword>
	<keyword>artemisinin-based combination therapy</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>efficacy</keyword>
</DOC>